Managing cellulitis in primary care
The skin normally provides an excellent barrier to infection, both due to providing an impenetrable layer for pathogenic bacteria, and by harbouring non-pathogenic bacteria which prevent the harmful ones from taking over [1],[2]. Yet this barrier can break down, and when this happens, there are plenty of bacteria waiting to take advantage of the opportunity. In many countries, around one-third of the population are asymptomatic carriers of Staph aureus, either constantly or intermittently [3]. It has been estimated that disrupting the skin merely by inserting one silk suture can increase the infectiousness of Staph aureus by a factor of 10,000 [4] .
However, possibly due to enthusiastic management of skin diseases with antibiotics, most patients with atopic dermatitis have been found to harbour Staph aureus on their skin, with higher infection rates than in non-atopic controls [3], and for antibiotic resistance to be high in these bacteria [2] .
The commonest pathogens for skin and soft tissue infections are Staph aureus and beta-haemolytic streptococci, although many other bacteria can cause infections once the skin defences are weakened [2],[3],[5],[6]. The mechanisms of attack are varied; in addition to the direct effects of colonisation of the body's tissues, they also can produce toxins which may be able to breach the skin's defences and enable the bacteria to penetrate the deeper tissues [2] .
Beta-haemolytic streptococci tend to cause cellulitis which spreads rapidly through the subcutaneous tissues thanks to the action of enzymes such as hyaluronidases produced by the bacteria, whereas staphylococcal infections tend to be more demarcated [3] .
More recently, they have also been shown to produce proteins which can act as 'superantigens'.
These bind directly to antigen-presenting cells and so cause polyclonal T cell activation, which has been implicated in the aggravation of atopic dermatitis, psoriasis and contact dermatitis, as well as the more rare but serious toxic shock syndrome and Kawasaki's syndrome [3] .
What is cellulitis?
Cellulitis is a diffuse suppurative inflammation of subcutaneous tissues [1]. In older people the leg is the usual site, whereas younger people tend to develop the condition in the upper body [7]. Patients admitted to hospital have an average stay of 10 days and 10% of patients suffer long term morbidity afterwards from persistent oedema, recurrent cellulitis and leg ulceration [8]. Of these patients, a portal of entry was found in just 55%. There is also a small risk of more serious complications in young children and immunocompromised adults such as gangrene, metastatic abscesses and sepsis [1].
Risk factors for cellulitis
As we have seen, cellulitis is more likely to follow some damage to the skin. One study found the following conditions in patients with cellulitis [9]:
Diabetes (50% of patients)
Previous cellulitis (50%)
Oedema (45%)
Peripheral vascular disease (40%)
Tinea pedis (32%) Another study showed that about 55% of patients with cellulitis of the leg had a previous minor injury or tinea pedis infection [8].
Periorbital cellulitis
Periorbital cellulitis is usually associated with paranasal sinusitis (43% in one study), trauma (25%) or dental infection (6%) . While the majority of infections are due to Staph aureus [10],[11], some cases in children have been associated with Haemophilus influenzae [12]. Both the number of cases specifically due to this bacterium, and the total number of cases have dropped since the Hib immunisation campaign began [13].
Diagnosing cellulitis
Clinical signsThe diagnosis of cellulitis is based on the clinical signs and symptoms [1],[7]
Common:
Localised redness, warmth and tenderness
Swelling
Less common:
Lymphangitis
Lymphadenitis
Mild fever and chills
Malaise
Investigations
Investigations are rarely helpful in cellulitis. White cell counts are mildly raised if at all [7] . Needle aspiration, Gram stains and blood cultures are usually negative [7],[12],[14],[15],[16], as are lumbar punctures for periorbital cellulitis in children [12]. On average, even culture of swabs grows pathogens in only about half of samples [11]. This means that diagnosis and treatment will always be empirical [15].
Necrotising facsciitis
Necrotising fasciitits is a very rare but serious infection which presents like cellulitis but causes fulminant tissue destruction [17]. It usually follows trauma to the skin, but this may be merely a contusion, burn or insect bite [18]. The infection spreads extremely rapidly and can cause multiorgan failure, adult respiratory distress syndrome [[18], with a 40% mortality rate [[19]. Most infections are polymicrobial with Gram positive and negative, aerobic and anaerobic bacteria, although Group A streptococci are the most common pathogens [18].
It can be difficult to distinguish between necrotising fasciitis and cellulitis. The main features of necrotising fasciitis are:
Oedema of the area with peau d'orange appearance [20]
Blistering and necrosis [19]
Crepitus of the tissues [19]
Pain out of proportion to the clinical findings [21]
Signs of systemic infection may be present [19], [20] Treatment should be started as soon as possible, and requires surgical debridement of the area and high dose intravenous antibiotics [19],[20],[21].
Management of cellulitis
Management of cellulitis is essentially with oral antibiotics, although rest and elevation of the affected part, moist heat and analgesia may be helpful [1],[7].
Recommended antibiotics are [22],[23]:
Penicillin V 500 mg QDS and Flucloxacillin 500 mg QDS for 7-14 days Cost: £6.60-£13.21
If allergic to penicillin:
Erythromycin 500 mg QDS for 7-14 days Cost :£6.16-£12.32
Co-amoxyclav 500/125 mg TDS for 7-14 days Cost: £15.73-£31.46 Other antibiotics may be of use if local sensitivities mean penicillins and erythromycin are less effective.
Fusidic acid 500 mg daily for 5-10 days was equally effective as flucloxacillin 500 mg TDS with cure rates of over 92% [3] Cost of fusidic acid: £6.47-£12.94
Azithromycin 500 mg on day 1 and 250 mg daily for days 2-5 was as effective as cephalexin 500 mg BD for 10 days [24] Cost of azithromycin: £13.43
Azithromycin 1.5 g in divided doses over 5 days was as effective as erythromycin 500 mg QDS for 7 days a [25] Cost of azithromycin: £13.43
Clindamycin, as an inhibitor of protein synthesis, should be used additionally for severe infections as it will inhibit toxin production [3] Cost of 300 mg QDS for 7-14 days: £25.48-£50.96
Antibiotic prophylaxis While recurrent attacks are common, there is little evidence that the use of prophylactic antibiotics can reduce recurrence. A study in China found that monthly injections of penicillin made no overall impact on the recurrence rate of cellulitis [26]. Eradicating Staph aureus in asymptomatic nasal carriers with monthly mupirocin ointment has been shown to reduce the number of skin infections as long as the treatment is continued [3], but the long-term use of prophylactic antibiotics carries a risk of encouraging the development of antibiotic resistance [3].
Chronic leg ulcers While chronic leg ulcers are always contaminated with bacteria, antibiotics should only be given if there are signs of cellulitis in the surrounding tissues [27].
References
1.Hacker SM. Common infections of the skin. Postgrad Med 1994;96(2):43-52. [Medline abstract]
2.Thestrup-Pedersen K. Bacteria and the skin: clinical practice and therapy update. Br J Dermatol 1998;139:1-3. [Medline abstract]
3.Veien NK. The clinician's choice of antibiotics in the treatment of bacterial skin infection. Br J Dermatol 1998;139:30-36. [Medline abstract]
4.Roth RR, James WD. Microbiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol 1989;22(5 Pt 1):879-883. [Medline abstract]
5.Brook I. Antimicrobial therapy of skin and soft tissue infection in children. J Am Podiatr Med Assoc 1993;83(7):398-405. [Medline abstract]
6.Baddour LM. Cellulitis syndromes: an update. Int J Antimicrob Agents 2000;14(2):113-116. [Medline abstract]
7.Ginsberg MB. Cellulitis: analysis of 101 cases and review of the literature. South Med J 1981;74(5):530-533. [Medline abstract]
8.Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J R Soc Med 1998;91(12):634-637. [Medline abstract]
9.Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis 1999;34(4):325-327. [Medline abstract]
10. Kanra G, Secmeer G, Gonc EN et al. Periorbital cellulitis: a comparison of different treatment regimens. Acta Paediatr Jpn 1996;38(4):339-342. [Medline abstract]
11.Chang CH, Lai YH, Wang HZ et al. Antibiotic treatment of orbital cellulitis: an analysis of pathogenic bacteria and bacterial susceptibility. J Ocul Pharmacol Ther 2000;16(1):75-79. [Medline abstract]
12.Schwartz GR, Wright SW. Changing bacteriology of periorbital cellulitis. Ann Emerg Med 1996;28(6):617-620. [Medline abstract]
13.Ambati BK, Ambati J, Azar N et al. Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology 2000;107(8):1450-1453. [Medline abstract]
14. Perl B, Gottehrer NP, Raveh D et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999;29(6):1483-1488. [Medline abstract]
15. Lutomski DM, Trott AT, Runyon JM et al. Microbiology of adult cellulitis. J Fam Pract 1988;26(1):45-48. [Medline abstract]
16. Aly AA, Roberts NM, Seipol KS et al. Case survey of management of cellulitis in a tertiary teaching hospital. Med J Aust 1996;165(10):553-556. [Medline abstract]
17.Childs SG. Necrotizing fasciitis: challenging management of a septic wound. Orthop Nurs 1999;18(2):11-17. [Medline abstract]
18.Fontes RA Jr, Ogilvie CM, Miclau T. Necrotizing soft-tissue infections. J Am Acad Orthop Surg 2000;8(3):151-158. [Medline abstract]
19. Adant JP, Bluth F, Fissette J. Necrotizing fasciitis: a life-threatening infection. Acta Chir Belg 1998;98(3):102-106. [Medline abstract]
20. Moss RL, Musemeche CA, Kosloske AM. Necrotizing fasciitis in children: prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996;31(8):1142-1146. [Medline abstract]
21. Leitch HA, Palepu A, Fernandes CM. Necrotizing fasciitis secondary to group A streptococcus. Morbidity and mortality still high. Can Fam Physician 2000;46:1460-1466.[Medline abstract]
22. British National Formulary , British Medical Association and the Royal Pharmaceutical Society of Great Britain, March 2000
23. Public Health Laboratory Service. Antibiotic guidance template for primary care. 2000.
24. Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis 1991;10(10):880-884. [Medline abstract]
25. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991;19(6):433-445. [Medline abstract]
26.Wang JH, Liu YC, Cheng DL et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997;25(3):685-689. [Medline abstract]
27. McClure CL. Common infections in the elderly. Am Fam Physician 1992;45(6):2691-2698. [Medline abstract]
JB Medical
0 Comments:
Post a Comment
<< Home